— Anaveon will present further progress in EXPAND-1, a Phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors —

Basel, December 10, 2025 – Anaveon, a global clinical stage, immuno-oncology company, will present a poster on its ANV600 program at the European Society of Medical Oncology – Immuno-Oncology (ESMO-IO) Congress 2025  being held from Wednesday, December 10, 2025, to Friday, December 12, 2025, in London, UK.

ANV600 has been developed to deliver IL-2Rβγ agonism specifically to PD-1⁺ cells while preserving the binding site for PD-1 checkpoint inhibitors. Results of the EXPAND-1 study showed that treatment with ANV600 resulted in a dose-dependent preferential stimulation of PD-1⁺ cells with higher absolute counts of CD8⁺ T cells and NK cells over regulatory T cells with good tolerability.

The abstract will be available on the ESMO-IO website, and the accompanying poster will be on display on the ESMO-IO 2025 meeting platform as well as on Anaveon’s website  (download poster here).

Poster # 256P – EXPAND-1, a Phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors

Authors: M. Imbimbo, E. Calvo, I. Korakis, P. Tomasini, S. Cousin, T. Goetze, K. Ouali, A. Desuki, V. Gambardella, G. Alonso, N. Steeghs, S. Ochsenreither, Y. F. Shao, A. M. Tsimberidou, R. Galot, A. V. Lacarra, M. Chisamore, K. Richter, R. Sachse, M. Joerger

The poster will be presented on Wednesday, December 10, 2025, between 5:15 pm and 6:30 pm (GMT) by Dr. Martina Imbimbo of Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.

Anaveon’s mission is to harness the power of the immune system for life-changing treatments. The company was founded in 2017 by scientists and industry experts, who aspire to invent and develop therapeutic treatments that benefit patients and society. Today, Anaveon is a clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.

ENDS

Media contact:
Benz Advisory
Beatrix Benz
Email:  beatrix.benz@benz-advisory.com
Tel: +41 79 256 77 73

About Anaveon:
Anaveon is an international biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compound ANV600 is currently in clinical trials in solid tumors.

Find out more at anaveon.com